Seeking Alpha

Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program

License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applications ...
Seeking Alpha

Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

-- European, International Strategies Advancing At-Pace with Significant Progress Throughout 2022, and Strong Position for 2023 -- We are also advancing our fixed-dose combination (FDC) program for ...
Macworld

FrontBase Developer Connection debuts

FrontBase Inc. today announced FrontBase Developer Connection (FDC), which the company bills as a developer rewards program. Under the terms of the new program, developers can earn points that will ...
Mena FN

Sagimet Biosciences And TAPI Announce Global License Agreement For Innovative Forms Of Resmetirom API For Sagimet's Fixed Dose Combination Program

License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applications ...